1932

Abstract

With the manufacture of imatinib, researchers introduced tyrosine kinase inhibitors (TKIs) into the clinical setting in 2000 to treat cancers; approximately fifteen other TKIs soon followed. Imatinib remains the most successful agent, whereas all the others have had modest effects on the cancers that they target. The current challenge is to identify the agents that need to be combined with TKIs to maximize their efficacy. One of the most promising approaches is to combine immune therapy with TKI treatment. In this review, the therapeutic potential of TKIs for treatment is discussed.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-pharmtox-011112-140341
2013-01-06
2024-06-13
Loading full text...

Full text loading...

/content/journals/10.1146/annurev-pharmtox-011112-140341
Loading
/content/journals/10.1146/annurev-pharmtox-011112-140341
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error